Skip to content
10-Q

Quarterly Report

TCR2 Therapeutics Inc.

0000950170-23-020832

← back to feed
Filed
May 11, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 1, 2023 39.26M sh
Shares Diluted Q1 2023 · Mar 31, 2023 39.22M sh
Shares Diluted Q1 2023 · Mar 31, 2022 38.51M sh
Capex Q1 2023 · Mar 31, 2023 $158K
Capex Q1 2023 · Mar 31, 2022 $1.91M
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$40.01M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$31.13M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $14.45M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $32.75M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $74.12M
Stockholders Equity Q1 2023 · Mar 31, 2023 $101.33M
Stockholders Equity Q1 2023 · Dec 31, 2022 $140.86M
Stockholders Equity Q1 2023 · Mar 31, 2022 $255.32M
Stockholders Equity Q1 2023 · Dec 31, 2021 $281.48M
Current Liabilities Q1 2023 · Mar 31, 2023 $47.47M
Current Liabilities Q1 2023 · Dec 31, 2022 $64.06M
Total Liabilities Q1 2023 · Mar 31, 2023 $50.18M
Total Liabilities Q1 2023 · Dec 31, 2022 $67.38M
Current Assets Q1 2023 · Mar 31, 2023 $140.49M
Current Assets Q1 2023 · Dec 31, 2022 $177.62M
Total Assets Q1 2023 · Mar 31, 2023 $151.51M
Total Assets Q1 2023 · Dec 31, 2022 $208.24M
Eps Diluted Q1 2023 · Mar 31, 2023 −$1.03
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.76
Eps Basic Q1 2023 · Mar 31, 2023 −$1.03
Eps Basic Q1 2023 · Mar 31, 2022 −$0.76
Sga Expense Q1 2023 · Mar 31, 2023 $8.2M
Sga Expense Q1 2023 · Mar 31, 2022 $6.32M
Rd Expense Q1 2023 · Mar 31, 2023 $29.27M
Rd Expense restated Q1 2023 · Mar 31, 2022 $22.32M
Net Income Q1 2023 · Mar 31, 2023 −$40.4M
Net Income Q1 2023 · Mar 31, 2022 −$29.12M
Operating Income Q1 2023 · Mar 31, 2023 −$41.51M
Operating Income Q1 2023 · Mar 31, 2022 −$29.2M